



VG Energy Enters into a Strategic Alliance with DAK Renewable Research for LipidMax Field Trials

SOURCE: Business Wire

San Marino, CA (PRWEB) May 23, 2013

SAN MARINO, Calif., May 23, 2013 /PRNewswire/ — VG Energy, an agricultural biotech company, announces today a strategic alliance with DAK Renewable Research to conduct field trials using LipidMax to increase the corn oil yield. VG Energy is a majority owned subsidiary of VG Life Sciences, Inc. (OTC Pink: [VGLS](#)).

VG Energy's exclusively licensed compound LipidMax selectively inhibits certain metabolic pathways to increase the oil yield in plants, possessing a wide variety of applications including biofuel and vegetable oils. This important discovery is called Metabolic Disruption Technology.

DAK Renewable Research headquartered in Brandon, South Dakota brings agricultural innovations together with investors. It is primarily focused on developing viable and cost-effective green energy solutions. DAK is providing twelve 2,000 ft² plots in South Dakota to measure the effect of LipidMax in corn oil production and test the robustness of LipidMax in field conditions. The compound will be applied at multiple stages in the growth cycle of the corn. The crop will reach maturity in mid-October and results will be announced shortly thereafter. All data from the results will be exclusively owned by VG Energy.

"We are excited to see our product take this leap from the lab to the field," says Haig Keledjian, CEO of VG Life Sciences. "Our goal with these tests is to further approach market commercialization and getting LipidMax closer to being in the hands of farmers."

The inventor of Metabolic Disruption Technology (MDT) is Karen Newell, PhD at Texas A&M University School of Medicine and Chief Scientist at VG Life Sciences. Dr. Marty Dickman, PhD at Texas A&M University, is the Chief Scientific Advisor for VG Life Sciences on the agricultural side of the business. Together Dr. Newell and Dr. Dickman are testing and developing exciting MDT agricultural applications including LipidMax.

"We have seen very positive lab results on oil yields using LipidMax and now we are anxious to see if we get similar yields in the field," said Dr. Dickman. "Yield is the watchword of every farmer and our partners at DAK Renewable Research are the perfect facilitators to bring this all together."

About VG Energy

VG Energy, Inc. is an agricultural biotech company that is a majority-owned subsidiary of VG Life Sciences Inc., a biotech company researching treatments for drug-resistant cancer, Lyme disease, Strep, Staph and Sepsis, and HIV/AIDS. VG Energy holds the exclusive worldwide license to the Metabolic Disruption Technology (MDT) patent rights for use in the increase of production of various oils from algae, plants and seeds. VG Energy's pivotal discoveries could allow the agricultural industry to increase production yields. For more information, please visit www.vgenenergy.net or www.VGLifeSciences.com.

About DAK Renewable Research

DAK Renewable Energy is committed to working towards a greener environment through the development, management and investment in projects related to ethanol, wind and biofuels. The directors of DAK are



supported by a team of talented individuals with extensive experience in agricultural, education and business development. For more information, please visit www.dakrenewableenergy.com.

Safe Harbor Statement and Forward-Looking Statements

This news release may contain forward-looking statements that involve risks and uncertainties associated with financial projections, milestone timelines, clinical development, regulatory approvals and other risks described by VG Life Sciences from time to time in its periodic reports. None of VG Life Sciences' drug compounds are approved by the US FDA or by any comparable regulatory agencies elsewhere in the world. Therefore, there can be no assurance that the forward-looking statements included in this release will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, the forward-looking statements should not be regarded as a representation by VG Life Sciences or any other person that the objectives and plans of VG Life Sciences will be achieved.

Contact:

Allie Trabucco, Corporate Communications
VG Life Sciences Inc.
Phone: (805) 879-9000
Email: atrabucco@vglifesciences.com

SOURCE VG Life Sciences Inc.